03:05 , Jun 30, 2018 |  BioCentury  |  Finance

Hidden in the rough

Judicious stock picking was especially important in the second quarter, as 57% of global biotech stocks saw their equity values decline. Volatility continued to roil global markets during the period and additional uncertainty looms with the...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...
19:59 , Jun 15, 2018 |  BC Week In Review  |  Company News

ICER panel says long-term value for Aimovig for migraines is intermediate

ICER's California Technology Assessment Forum (CTAF) voted that the long-term value of calcitonin gene-related peptide (CGRP) inhibitor Aimovig erenumab for patients with chronic migraine who had previously failed other preventative migraine treatments was intermediate, while...
20:40 , Jun 14, 2018 |  BC Week In Review  |  Clinical News

Allergan's atogepant meets in Phase IIb/III to prevent migraine

Allergan plc (NYSE:AGN) said all doses of oral atogepant (MK-8031) met the primary endpoint in the double-blind, U.S. Phase IIb/III CGP-MD-01 trial to prevent episodic migraine. The company declined to disclose next steps for the...
21:23 , Jun 11, 2018 |  BC Extra  |  Clinical News

Allergan's atogepant meets in Phase IIb/III to prevent migraine

Allergan plc (NYSE:AGN) said all doses of oral atogepant (MK-8031) met the primary endpoint in the Phase IIb/III CGP-MD-01 trial to prevent episodic migraine. The company declined to disclose next steps for the small molecule...
18:29 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

CHMP recommendations include Aimovig, orphan candidates

Among a host of positive recommendations announced on June 1, EMA's CHMP backed approval of migraine therapy Aimovig erenumab and Orphan Drug designees Tegsedi inotersen for hereditary transthyretin (TTR) amyloidosis and Myalepta metreleptin for leptin...
23:11 , Jun 7, 2018 |  BC Week In Review  |  Company News

ICER updates cost-effectiveness estimates for CGRP inhibitors for migraines

ICER released an evidence report May 31 evaluating calcitonin gene-related peptide (CGRP) inhibitors for migraine prevention that calculated more favorable long-term cost-effectiveness ratios than in its April draft evidence report. ICER updated the cost-effectiveness analyses...
22:08 , Jun 1, 2018 |  BC Extra  |  Company News

Aimovig price improves ICER's migraine outlook

ICER released an evidence report evaluating calcitonin gene-related peptide (CGRP) inhibitors for migraine prevention that calculated more favorable long-term cost-effectiveness ratios than in its April draft evidence report. ICER updated the cost-effectiveness analyses using the...
14:44 , Jun 1, 2018 |  BC Extra  |  Company News

CHMP's recommendations include Aimovig, Orphan candidates

Among a host of positive recommendations announced Friday, EMA's CHMP backed approval of migraine therapy Aimovig erenumab and Orphan Drug designees Tegsedi inotersen for hereditary transthyretin (TTR) amyloidosis and Myalepta metreleptin for leptin deficiency. The committee...
19:42 , May 18, 2018 |  BC Week In Review  |  Clinical News

FDA approves Aimovig as first CGRP inhibitor for migraines

FDA approved Aimovig erenumab from Amgen Inc. (NASDAQ:AMGN) and Novartis AG (NYSE:NVS; SIX:NOVN) late on May 17 to prevent migraine in adults. The drug is the first calcitonin gene-related peptide (CGRP) inhibitor approved for the...